Delving into the Latest Updates on Bumetanide analog(NeuroPro Therapeutics, Inc.) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

bumetanide analog(NeuroPro Therapeutics, Inc.), NPT 2042, NPT-2042

+ [1]

Target

NKCC2

Action

inhibitors

Mechanism

NKCC2 inhibitors(Sodium-(potassium)-chloride cotransporter 2 inhibitors)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Epilepsy, GeneralizedSeizuresEpilepsy, Reflex+ [2]

Inactive Indication-

Originator Organization

NeuroPro Therapeutics, Inc.Startup

Active Organization

NeuroPro Therapeutics, Inc.Startup

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 80 mg BID orally or matching placebo BID in each of two treatment periods.

Start Date11 Mar 2025

Sponsor / Collaborator

NeuroPro Therapeutics, Inc.Startup

NCT06525649

/ RecruitingPhase 1

A Double Blind, Randomized, Cross-over Study Examining the Suppression of the Photoparoxysmal EEG Response With NPT 2042

A double-blind, placebo-controlled, crossover trial to investigate the PPR of approximately 5 subjects with a known stable PPR on EEG, using 2 doses of NPT 2042 compared to placebo.

Start Date21 Aug 2024

Sponsor / Collaborator

NeuroPro Therapeutics, Inc.Startup

NCT05503511

/ CompletedPhase 1

A Single-center, Randomized, Placebo Controlled, Double-blind, Ascending Single-dose and Repeated-dose Trial to Determine the Safety and Pharmacokinetic Profile of NPT 2042 Soft-Gelatin Capsules Administered Orally to Healthy Adult Subjects

Study NPT 2042 CL 101 is a first in human (FIH) study to evaluate the safety and pharmacokinetics (PK) of single and repeated ascending doses of NPT 2042 in healthy adult male and female subjects.

Start Date20 Oct 2022

Sponsor / Collaborator

NeuroPro Therapeutics, Inc.Startup

100 Clinical Results associated with Bumetanide analog(NeuroPro Therapeutics, Inc.)

Login to view more data

100 Translational Medicine associated with Bumetanide analog(NeuroPro Therapeutics, Inc.)

Login to view more data

100 Patents (Medical) associated with Bumetanide analog(NeuroPro Therapeutics, Inc.)

Login to view more data

100 Deals associated with Bumetanide analog(NeuroPro Therapeutics, Inc.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Epilepsy, Generalized	Phase 2	United States	NeuroPro Therapeutics, Inc.Startup	11 Mar 2025
Seizures	Phase 2	United States	NeuroPro Therapeutics, Inc.Startup	11 Mar 2025
Epilepsy, Reflex	Phase 1	United States	NeuroPro Therapeutics, Inc.Startup	21 Aug 2024
Alzheimer Disease	Phase 1	United States	NeuroPro Therapeutics, Inc.Startup	20 Oct 2022
Drug Resistant Epilepsy	Phase 1	United States	NeuroPro Therapeutics, Inc.Startup	20 Oct 2022